Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis

• Main Authors: Zhiyun Cheng, Yinghui Lv, Suqiu Pang, Ruyu Bai, Mingxi Wang, Shuyu Lin, Tianwen Xu, Duncan Spalding, Nagy Habib, Ruian Xu
• Format: Article
• Language: English
• Published: Elsevier 2015-05-01
• Series: Acta Pharmaceutica Sinica B
• Subjects: Kallistatin; Liver cirrhosis; Biomarker; Liver fibrosis; Hepatocellular carcinoma
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211383515000313

Kallistatin, which protects organs and cells against inflammation, fibrosis and oxidative stress, is mainly synthesized and secreted in liver. However, its relationship to human liver disease remains unclear. The purpose of this study was to explore the relationship between serum kallistatin and clinical evidence of both cirrhosis and hepatocellular carcinoma (HCC), and to determine if serum kallistatin levels could be used as a diagnostic indicator of hepatic health status, especially human liver cirrhosis (LC). Our cohort consisted of 115 patients with clinically proven liver fibrosis (LF), LC, or HCC by liver biopsies, and 31 healthy controls (CON). Serum kallistatin levels were quantified by ELISA. Results of the present study demonstrated that irrespective of the underlying etiology, serum kallistatin levels were significantly lower in the LF/LC group when compared with the CON group. A decrease in serum kallistatin levels appeared to reflect the extent of cirrhosis, with the lowest levels associated with higher grades of cirrhosis. Patients with LC had a noticeable correlation between serum kallistatin levels and other serum biochemical indicators. The area under the curve (AUC) for LC, viral liver cirrhosis (VLC) and alcoholic liver cirrhosis (ALC) was 0.845, 0.757 and 0.931, respectively. In conclusion, our findings demonstrated that kallistatin, a plasma protein produced by the liver, can be a useful and reliable diagnostic indicator of hepatic health status, especially for LC.